Prestige Consumer Healthcare (PBH) has drawn fresh attention as investors weigh its recent share performance against underlying fundamentals, including annual revenue of US$1.1b and net income of US$186.5m from its over the counter product portfolio.

At a share price of US$54.59, Prestige Consumer Healthcare has seen a 17.7% 90 day share price decline and a 37.28% 1 year total shareholder return decline. This suggests recent momentum has weakened compared with its longer term 5 year total shareholder return of 12.33%.

If you are comparing PBH with other health focused opportunities, it may be a good moment to widen your watchlist using our curated set of 35 healthcare AI stocks

So with annual revenue of US$1.1b, net income of US$186.5m, a recent 37.28% 1 year total shareholder return decline, and an indicated intrinsic discount of 66.55%, is this stock undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 30.5% Undervalued

Prestige Consumer Healthcare's most followed narrative pegs fair value at $78.50 per share, compared with the last close of $54.59. This frames a sizeable valuation gap investors are trying to understand.

Prestige's supply chain investments, specifically the acquisition of Pillar5 and onboarding new suppliers for Clear Eyes, are set to resolve current supply constraints and support normalization and eventual growth of revenues, especially in the high-demand eye care segment, from the second half of fiscal '26 and into fiscal '27.

Want to see what is baked into that valuation gap? The narrative leans on a clear roadmap for revenue, margins and earnings, plus a future earnings multiple that needs to line up. The full picture sets out how all three work together to support that fair value.

Result: Fair Value of $78.50 (UNDERVALUED)

However, the picture is not one way. Ongoing supply constraints around Clear Eyes and heavy reliance on a handful of mature core brands are both weighing on that upside case.

Next Steps

With sentiment clearly split between risks and rewards, are you ready to look past the headline numbers and check the data for yourself? To see how those concerns and opportunities compare in one place, review the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you might miss opportunities that fit your style better, so put a few more quality ideas on your radar today.

• Target consistent cash generators by scanning companies in the 12 dividend fortresses that may suit an income focused watchlist.
• Hunt for quality at a sensible price by checking companies in the 51 high quality undervalued stocks that match your return and risk preferences.
• Prioritise resilience first by reviewing stocks in the 72 resilient stocks with low risk scores before chasing higher volatility opportunities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.